Literature DB >> 19008897

Immunotherapy of autoimmunity and cancer: the penalty for success.

Rachel R Caspi1.   

Abstract

Advances in our understanding of autoimmunity and tumour immunity have led to improvements in immunotherapy for these diseases. Ironically, effective tumour immunity requires the induction of the same responses that underlie autoimmunity, whereas autoimmunity is driven by dysregulation of the same mechanisms that are involved in host defence and immune surveillance. Therefore, as we manipulate the immune system to treat cancer or autoimmunity, we inevitably unbalance the vital mechanisms that regulate self tolerance and antimicrobial resistance. This Science and Society article aims to dissect the conundrum that is inherent to the concept of immunotherapy and highlights the need for new and more specific therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19008897      PMCID: PMC2764117          DOI: 10.1038/nri2438

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  59 in total

Review 1.  Monoclonal antibody therapy of cancer.

Authors:  Gregory P Adams; Louis M Weiner
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

Review 2.  TNFalpha blockade in human diseases: an overview of efficacy and safety.

Authors:  Jan Lin; David Ziring; Sheetal Desai; Sungjin Kim; Maida Wong; Yael Korin; Jonathan Braun; Elaine Reed; David Gjertson; Ram Raj Singh
Journal:  Clin Immunol       Date:  2007-10-04       Impact factor: 3.969

Review 3.  Immune therapies of autoimmune diseases: are we approaching a real cure?

Authors:  Lucienne Chatenoud
Journal:  Curr Opin Immunol       Date:  2006-09-29       Impact factor: 7.486

Review 4.  T-cell responses to autoantigens in IDDM. The search for the Holy Grail.

Authors:  B O Roep
Journal:  Diabetes       Date:  1996-09       Impact factor: 9.461

5.  Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.

Authors:  Ajay V Maker; Giao Q Phan; Peter Attia; James C Yang; Richard M Sherry; Suzanne L Topalian; Udai S Kammula; Richard E Royal; Leah R Haworth; Catherine Levy; David Kleiner; Sharon A Mavroukakis; Michael Yellin; Steven A Rosenberg
Journal:  Ann Surg Oncol       Date:  2005-10-21       Impact factor: 5.344

Review 6.  Acetylcholine receptors and myasthenia.

Authors:  J M Lindstrom
Journal:  Muscle Nerve       Date:  2000-04       Impact factor: 3.217

Review 7.  Development of anti-TNF therapy for rheumatoid arthritis.

Authors:  Marc Feldmann
Journal:  Nat Rev Immunol       Date:  2002-05       Impact factor: 53.106

8.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

Authors:  Kimberly E Beck; Joseph A Blansfield; Khoi Q Tran; Andrew L Feldman; Marybeth S Hughes; Richard E Royal; Udai S Kammula; Suzanne L Topalian; Richard M Sherry; David Kleiner; Martha Quezado; Israel Lowy; Michael Yellin; Steven A Rosenberg; James C Yang
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

9.  Cellular autoimmunity to retinal specific antigens in patients with Behçet's disease.

Authors:  J H Yamamoto; M Minami; G Inaba; K Masuda; M Mochizuki
Journal:  Br J Ophthalmol       Date:  1993-09       Impact factor: 4.638

Review 10.  Bacterial targeted tumour therapy-dawn of a new era.

Authors:  Ming Q Wei; Asferd Mengesha; David Good; Jozef Anné
Journal:  Cancer Lett       Date:  2008-01-18       Impact factor: 8.679

View more
  51 in total

Review 1.  Carbohydrate-based cancer vaccines: target cancer with sugar bullets.

Authors:  Chang-Cheng Liu; Xin-Shan Ye
Journal:  Glycoconj J       Date:  2012-06-06       Impact factor: 2.916

2.  Reproductive immunology: a focus on the role of female sex hormones and other gender-related factors.

Authors:  Elena Peeva
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

3.  Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.

Authors:  Ami A Shah; Antony Rosen; Laura Hummers; Fredrick Wigley; Livia Casciola-Rosen
Journal:  Arthritis Rheum       Date:  2010-09

4.  Targeting lymphotoxin depletes pathogenic T cells.

Authors:  Anna M Hansen; Rachel R Caspi
Journal:  Nat Med       Date:  2009-07       Impact factor: 53.440

5.  No human protein is exempt from bacterial motifs, not even one.

Authors:  Brett Trost; Guglielmo Lucchese; Angela Stufano; Mik Bickis; Anthony Kusalik; Darja Kanduc
Journal:  Self Nonself       Date:  2010-10

Review 6.  Evidence-Based Immunotherapeutic Effects of Herbal Compounds on Humoral Immunity: Ancient and New Approaches.

Authors:  Fatemeh Nejatbakhsh; Mohammad Ali Zareian; Mahdi Yaseliani; Hassan Abolhassani
Journal:  Chin J Integr Med       Date:  2021-03-24       Impact factor: 1.978

Review 7.  A look at autoimmunity and inflammation in the eye.

Authors:  Rachel R Caspi
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

8.  Combination Treatment with Antigen-Specific Dual-Sized Microparticle System Plus Anti-CD3 Immunotherapy Fails to Synergize to Improve Late-Stage Type 1 Diabetes Prevention in Nonobese Diabetic Mice.

Authors:  J M Stewart; A L Posgai; J J Leon; M J Haller; B G Keselowsky
Journal:  ACS Biomater Sci Eng       Date:  2020-09-10

9.  Functionalization of iron oxide nanoparticles with clove extract to induce apoptosis in MCF-7 breast cancer cells.

Authors:  T Thenmozhi
Journal:  3 Biotech       Date:  2020-02-01       Impact factor: 2.406

10.  Potential target antigens for a universal vaccine in epithelial ovarian cancer.

Authors:  Renee Vermeij; Toos Daemen; Geertruida H de Bock; Pauline de Graeff; Ninke Leffers; Annechien Lambeck; Klaske A ten Hoor; Harry Hollema; Ate G J van der Zee; Hans W Nijman
Journal:  Clin Dev Immunol       Date:  2010-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.